Vogenx (VOGX) Stock Analysis

What Vogenx does

Vogenx is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapeutics for the treatment of serious diseases associated with dysfunctions in human metabolism, including post-bariatric hypoglycemia (PBH) and gastroparesis. The company's lead product candidate is mizagliflozin, an orally administered, small molecule drug candidate being developed for the treatment of PBH, gastroparesis, and GIP-dependent Cushing's Syndrome.

Key metrics

ETFs linked to VOGX

Broad-market and Healthcare sector ETFs an investor holding Vogenx is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how VOGX fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Vogenx?

Vogenx trades under the ticker VOGX on NASDAQ.

Which exchange is VOGX listed on?

VOGX is listed on NASDAQ.

What sector does Vogenx operate in?

Vogenx is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze VOGX in a portfolio?

PortView shows VOGX's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.